Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Margarida Espírito-Santo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic Variants Associated with Response to GLP-1 Receptor Agonists in Diabetes and Obesity

    by Mónica T. Fernandes, Joana C. Dias, Margarida Espírito-Santo, Maria Dulce Estêvão, Ana Luísa De Sousa-Coelho

    Genetic variation may contribute to interindividual differences in the efficacy and tolerability of glucagon-like peptide-1 receptor agonists (GLP-1RAs), although the available evidence remains limited. Certain gene variants may underlie variability in glycemic control and weight loss outcomes among patients treated with GLP-1RAs for diabetes and/or obesity. A better understanding of these genetic variations could have significant implications for the development of personalized medicine, contributing to predicting patient responses to GLP-1RAs. Within this review, we collected and synthesized information from different studies about genetic variants that have been reported to be associated with altered therapeutic response to GLP-1RAs, mostly in GLP1R, but also in TCF7L2 and PNPLA3 genes. For the same variants, the differences obtained in the outcomes were, however, inconsistent between studies. Such disparities may partly reflect the diversity of the outcomes analyzed, the specific GLP-1RA in use, and/or the characteristics of each population. Additional genes, such as PPARD, WFS1 and VTRNA2-1, exhibited differences in at least one study. Although still limited, considering the fast expansion of the prescription of this therapeutic class, these results reflect the need for additional studies, before enabling the implementation of pharmacogenetics in clinical practice.

  • Open Access

    Safety Analysis of Pazopanib in Advanced and Metastatic Renal Cell Carcinoma: Insights From a Real‐World Pharmacovigilance Study

    by Frederico Fonseca, Lília Leonardo, Alexandre Baptista, Liliana Pedro, Maria Luísa Pereira, Nuno Landeiro, Margarida Espírito-Santo

    Renal cell carcinoma is the most common type of kidney cancer, accounting for approximately 90% of all cases. Pazopanib, a tyrosine kinase inhibitor, has emerged as an effective treatment option for advanced and metastatic renal cell carcinoma, demonstrating progression‐free survival benefits compared to placebo or interferon in previous Phase 3 clinical trials. However, real‐world data on its safety profile remain limited, underscoring the need for observational studies to assess the efficacy and safety of approved treatments in clinical practice. This retrospective observational study aims to evaluate the real‐world safety of pazopanib in patients with advanced renal cell carcinoma, providing clinical safety data from a hospital unit in the Alentejo region, Portugal, between 2015 and 2024. A total of 22 patients were included in the study, with a median age of 69 years (range: 45–86); the majority were male. The results revealed a higher incidence of adverse drug reactions compared to clinical trials, with hematological and hepatic toxicities being the most common. Thrombocytopenia was observed in 81.8% of patients, while hepatic impairment was reported in 68.2%. Dose adjustments due to analytical intolerance were required in 54.5% of cases. The study also assessed drug interactions in eligible participants within a real‐world clinical setting, revealing a high prevalence of potential drug interactions. On average, 1.36 interactions per patient were identified, with 73.3% classified as high‐risk (Category X). These findings highlight the importance of active pharmacovigilance in optimizing drug safety and treatment outcomes. Strategies such as personalized dosing, medication reconciliation, and close monitoring by clinical pharmacists are essential to mitigate risks and improve patient care. The safety profile and tolerability were found to be consistent with that reported in previous pivotal and real‐world evidence studies, underscoring the need for further research to refine treatment protocols and enhance patient outcomes.


  • Open Access

    Telehealth for Integrated Cardiovascular and Diabetes Management: A Scoping Review

    by Maria Dulce Estêvão, Mónica Teotónio Fernandes, Ana Luísa De Sousa-Coelho, Margarida Espírito-Santo, Tânia Nascimento

    Cardiovascular disease (CVD) and diabetes mellitus represent major global health challenges, frequently co‐occurring and mutually exacerbating. Telehealth interventions offer a promising approach for their management, with potential to improve patient outcomes, enhance access to care, and increase cost‐effectiveness. This review synthesized existing evidence from randomized controlled trials (RCTs) and observational studies to evaluate the effectiveness of telehealth interventions for the management of diabetes, focusing on CVD risk, and to identify critical research gaps. A systematic literature search was conducted across major databases (PubMed, Web of Science, and Scopus) to identify studies meeting predefined eligibility criteria, considering digital tools for remote monitoring, consultation, education, and medication management. After the screening of 3041 articles, six studies met the inclusion criteria. Telehealth interventions utilized a range of digital health tools, including mobile applications, artificial intelligence–powered clinical decision aids, electronic consultations, and integrated remote monitoring platforms. Although direct assessment of composite cardiovascular risk was largely absent, the included studies reported several clinical parameters associated with cardiovascular health, namely, blood pressure, lipid profile, and glycated hemoglobin. Telehealth interventions implemented for individuals with Type 2 diabetes mellitus demonstrated promising potential in improving glycemic control and supporting self‐management. However, their effectiveness in managing broader cardiovascular risk factors remains less clear due to inconsistent reporting and heterogeneous intervention designs.


  • Open Access

    Potential Impact of Metabolic Syndrome Control on Cardiovascular Risk in Elderly Patients with Diabetes: A Cross-Sectional Study

    by Tânia Nascimento, Margarida Espírito-Santo, Adriana Gonçalves, Ezequiel Pinto, Ana Luísa De Sousa-Coelho, Maria Dulce Estêvão

    Metabolic syndrome (MS), a complex pathology with features like abnormal body fat distribution, insulin resistance, and dyslipidaemia, contributes to higher cardiovascular (CV) risk. A cross-sectional study including 87 individuals assessed CV risk score in elderly patients with type 2 diabetes and MS in Algarve, Portugal. The 10-year CV risk score was estimated using the ADVANCE risk score calculator. The reductions in CV risk score were estimated by adjusting the data inputted on the online tool to achieve systolic blood pressure (SBP) p = 0.028). Hypothetical risk score reductions show that lowering SBP to <130 mmHg could significantly lower the risk score by an average of 9.2% (CI: 7.7–10.7), whereas 34.5% of the participants would be out of the diagnostic criteria for MS. When comparing each potential intervention with current risk score, all interventions significantly reduce the 10-year CV risk score. The study highlights the potential of blood pressure control in reducing CV risk score and the importance of multifaceted risk score reduction strategies.


  • Open Access

    Potential Impact of Metabolic Syndrome Control on Cardiovascular Risk in Elderly Patients with Diabetes: A Cross-Sectional Study

    by Tânia Nascimento, Margarida Espírito-Santo, Adriana Gonçalves, Ezequiel Pinto, Ana Luísa De Sousa-Coelho, Maria Dulce Estêvão

    Metabolic syndrome (MS), a complex pathology with features like abnormal body fat distribution, insulin resistance, and dyslipidaemia, contributes to higher cardiovascular (CV) risk. A cross-sectional study including 87 individuals, assessed CV risk in elderly patients with type 2 diabetes and MS in Algarve, Portugal. The 10-year CV risk was estimated using the ADVANCE risk score calculator. The reductions in CV risk were estimated by adjusting the data inputted on the online tool to achieve systolic blood pressure (SBP) <130 or <120 mmHg, and LDL-cholesterol <70 mg/dL. Beyond waist circumference, the mean number of clinical features of MS was 3.14±0.84, without significant sex differences. The mean CV risk was 22.5% (CI: 20.3-24.7). Sex-specific analysis showed higher risk in males (24.2%, CI: 21.3-27.0) vs. females (19.7%, CI: 16.2-23.3; p=0.028). Hypothetical risk reductions show that lowering SBP to <130 mmHg could significantly lower the risk by an average of 9.2% (CI: 7.7-10.7), whereas 34.5% of the participants would be out of the diagnostic criteria for MS. When comparing each potential intervention with current risk, all interventions significantly reduce the 10-years CV risk. The study highlights the potential of blood pressure control in reducing CV risk and the importance of multifaceted risk reduction strategies.

  • Open Access

    Preface: VII Poster Sunset Session—ESSUAlg 2024

    by Ana Luísa De Sousa-Coelho, Mónica T. Fernandes, M. Dulce Estêvão, Margarida Espírito-Santo, Luis Braz, Tânia Nascimento

    The event “Poster Sunset Session” began in 2017 at the School of Health of the University of Algarve (ESSUAlg), bringing the premise that scientific knowledge depends on research and critical analysis and that the exchange of ideas and information is an essential part of the continuous development process

  • Open Access

    Statement of Peer Review

    by Ana Luísa De Sousa-Coelho, Mónica T. Fernandes, M. Dulce Estêvão, Margarida Espírito-Santo, Luis Braz, Tânia Nascimento

    In submitting conference proceedings to Proceedings, the volume editors of the proceedings certify to the publisher that all papers published in this volume have been subjected to peer review administered by the volume editors

  • Open Access

    Exploring Adverse Drug Reactions in Psychotropic Medications: A Retrospective Analysis of Portuguese Pharmacovigilance Data

    by Ana Bandarra, César Costa, Kristina Angelova, Lília Leonardo, Margarida Espírito-Santo

    Psychotropic drugs (PDs) include anxiolytics, sedatives and hypnotics, antidepressants, and antipsychotics, and they are available as medicines with different safety profiles. Given Portugal’s high anxiolytic consumption and the rising prevalence of mental disorders, safety monitoring is crucial. This study aimed to analyze the individual case safety reports (ICSR) of suspected adverse drug reactions (ADRs) related to PDs, obtained through spontaneous reporting, and recorded in the Portuguese National Pharmacovigilance System between January 2017 and December 2021. This observational and retrospective study analyzed the ICSRs of suspected ADRs to PDs. Most reports pertained to female individuals (67.78%) between 18 and 64 years of age (63.71%). The pharmaceutical industry was the primary source of these reports (62.16%). Antidepressants were responsible for most ICSRs (61.90%). At least one serious ADR was recorded in 58.44% of the reports, and 43.84% of ADRs evolved into “cure”. The most-observed ADRs were nausea (10.92%), dizziness (10.70%), and off-label use (10.30%). In the causality assessment, 45.49% of ADRs were classified as “possible”, and only 4.96% were classified as “definitive”. The current analysis helps to strengthen the safety evidence for PDs. In the future, some measures could be implemented to improve the use of and/or access to PDs, as well as to reinforce the rate of suspected ADR reports within the community, contributing to the safety data available.


  • Open Access

    Digital Solutions Available to Be Used by Informal Caregivers, Contributing to Medication Adherence: A Scoping Review

    by Margarida Espírito-Santo, Sancha Santos, Maria Dulce Estêvão

    Medication adherence is essential for managing chronic diseases and achieving optimal health outcomes. However, this process is often challenging, particularly for patients with complex care needs. Informal caregivers play a pivotal role in supporting medication management, but they may face resource limitations and a lack of necessary support. Digital health tools offer a promising avenue to enhance medication adherence by providing reminders, education, and remote monitoring capabilities. This scoping review aimed to identify and evaluate digital solutions available to informal caregivers for improving medication adherence. A systematic search of PubMed and Web of Science was conducted using relevant keywords. Four studies were included in the review, examining a variety of digital tools including mobile apps, SMS messaging, and wearable devices. These tools demonstrated efficacy in improving medication adherence, managing disease symptoms, and enhancing quality of life for patients and caregivers. Digital health interventions hold the potential to revolutionize medication adherence among chronic disease patients. By empowering informal caregivers, these tools can bridge the gaps in medication management and contribute to better health outcomes. Further research is warranted to optimize the design, implementation, and evaluation of digital interventions for medication adherence.


  • Open Access

    AUTOMEDICAÇÃO: HÁBITOS DURANTE UM PERÍODO DE PANDEMIA – ESTUDO TRANSVERSAL

    by Margarida Espírito-Santo, M. Dulce Estêvão, Erica Campos

    A automedicação é uma prática muito comum e a pandemia de COVID-19 poderá ter criado condições para haver um maior recurso às farmácias comunitárias, particularmente em situações de doença ligeira. Esse estudo teve como objetivo analisar os hábitos de automedicação de uma amostra da população Portuguesa durante o período inicial da pandemia (março-novembro 2020), identificar os medicamentos não sujeitos a receita médica (MNSRM) e suplementos alimentares mais consumidos, bem como as situações que levaram os indivíduos a recorrer à automedicação e a informação sobre estes produtos. Foi realizado um estudo transversal, observacional, através da aplicação de um questionário com recurso a uma plataforma da internet, durante o mês de dezembro 2020. Os dados foram obtidos de forma anónima, e analisados com o programa IBM SPSS v26. A amostra em análise era composta por 170 indivíduos, tendo-se verificado que a pandemia parece não ter afetado a frequência de ida à farmácia. As situações que mais levaram as pessoas a recorrer à automedicação foram dores de cabeça e dores musculares. Os medicamentos mais utilizados neste período pelos participantes neste estudo foram os analgésicos e os anti-inflamatórios. Apesar de todas as restrições impostas pela situação pandémica, parece não ter havido um impacto negativo no recurso às farmácias comunitárias, nem um aumento significativo da prática de automedicação. Foi também assinalado o papel relevante dos profissionais de Farmácia, em particular nas situações de automedicação, como fonte de informação sobre o uso dos medicamentos e dos suplementos alimentares.